Genetic Disorders Clinical Trial
Official title:
A Phase II Exploratory, Open-label Study of the Safety and Efficacy of Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
The purpose of this single-center study is to explore the efficacy, safety, tolerability and pharmacokinetics/pharmacodynamics of recombinant human C1 inhibitor in the treatment of acute attacks in patients with hereditary angioedema.
n/a
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00705055 -
Face Anthropometric Pattern Recognition Technology for Computer Aided Diagnosis of Human Genetic Disorders.
|
N/A | |
| Completed |
NCT00851409 -
A Study of the Safety and Immunogenicity of Repeated rhC1INH Administration
|
Phase 2 | |
| Completed |
NCT00262301 -
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
|
Phase 3 | |
| Completed |
NCT01902901 -
Clinical Implementation of Carrier Status Using Next Generation Sequencing
|
N/A | |
| Completed |
NCT00578435 -
Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis
|
Phase 2 | |
| Recruiting |
NCT03911531 -
Whole Exome Sequencing and Whole Genome Sequencing for Nonimmune Fetal/Neonatal Hydrops
|
||
| Completed |
NCT01401257 -
Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A
|
Phase 2 | |
| Completed |
NCT00262288 -
Recombinant Human C1 Inhibitor for the Treatment of Acute Attacks in Patients With Hereditary Angioedema
|
Phase 2/Phase 3 | |
| Not yet recruiting |
NCT00214448 -
Reproducibility of the Array-Based Comparative Genomic Hybridization (aCGH) System Using Whole Blood Samples
|
N/A |